News Image

EXELIXIS INC (NASDAQ:EXEL) - An Undervalued Biotech Stock With Strong Fundamentals

By Mill Chart

Last update: Jul 2, 2025

EXELIXIS INC (NASDAQ:EXEL) was identified by our Decent Value stock screener as a company with solid fundamentals and an attractive valuation. The biotech firm specializes in developing treatments for difficult-to-treat cancers and currently has four marketed products, including its flagship drug cabozantinib.

EXELIXIS stock chart

Valuation Highlights

EXEL scores an 8/10 on valuation, indicating it may be priced below its intrinsic value:

  • P/E Ratio: At 19.83, it trades below both the industry average (72.42) and the S&P 500 (27.21).
  • Forward P/E: 16.44, cheaper than 93.9% of biotech peers.
  • Enterprise Value/EBITDA: Ranks better than 96% of the industry, suggesting undervaluation.
  • Price/Free Cash Flow: More affordable than 95% of competitors.

Financial Health

With a 9/10 health rating, EXEL maintains a strong balance sheet:

  • No Debt: A rare advantage in biotech, eliminating interest expenses and default risk.
  • Liquidity: Current ratio of 3.50 and quick ratio of 3.44 ensure short-term obligations are easily met.
  • Altman-Z Score: 12.21 signals minimal bankruptcy risk, outperforming 89% of peers.

Profitability Strengths

The company earns an 8/10 profitability score:

  • Margins: Gross margin of 96.78% and operating margin of 35.43% rank in the top 3% of the industry.
  • Returns: ROA of 22.68% and ROE of 30.20% outperform 98% and 97% of biotech firms, respectively.
  • Consistent Earnings: Profitable for five consecutive years with positive operating cash flow.

Growth Potential

EXEL’s 8/10 growth rating reflects strong expansion:

  • Revenue Growth: Up 24.5% YoY, with a 17.5% 5-year CAGR.
  • EPS Growth: Surged 205.6% over the past year, with a 12.7% 5-year average.
  • Future Estimates: Analysts project 25.8% annual EPS growth and 11.2% revenue growth.

Our Decent Value screener lists more stocks with similar characteristics.
For a deeper dive, review the full fundamental analysis of EXEL.

Disclaimer

This is not investment advice. Always conduct your own research before making financial decisions.

EXELIXIS INC

NASDAQ:EXEL (7/1/2025, 8:19:55 PM)

Premarket: 43.5 -0.12 (-0.28%)

43.62

-0.46 (-1.03%)



Find more stocks in the Stock Screener

EXEL Latest News and Analysis

ChartMill News Imagea minute ago - ChartmillEXELIXIS INC (NASDAQ:EXEL) - An Undervalued Biotech Stock With Strong Fundamentals

EXELIXIS (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, zero debt, and robust growth prospects, making it a candidate for value investors.

ChartMill News Image2 days ago - ChartmillEXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Technical Breakout Potential

EXELIXIS (NASDAQ:EXEL) is a strong growth stock with breakout potential, backed by robust earnings, revenue growth, and a healthy technical setup.

ChartMill News Image4 days ago - ChartmillEXELIXIS INC (NASDAQ:EXEL) – A High Growth Momentum Stock with Strong Technical Setup

EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors. The stock is consolidating with clear support levels, suggesting a potential breakout opportunity.

ChartMill News Image8 days ago - ChartmillEXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in Growth and Momentum Investing

EXELIXIS INC (NASDAQ:EXEL) shows strong growth momentum and meets Minervini’s trend criteria, making it a stock to watch for high-growth investors.

ChartMill News Image9 days ago - ChartmillThese stocks are moving in today's pre-market session

Wondering what's happening in Monday's pre-market session? Find an overview in this article.

Mentions: HUSA NINE MRIN CDTX ...

ChartMill News Image15 days ago - ChartmillEXELIXIS INC (NASDAQ:EXEL) – A Strong Contender for Growth Investors

EXELIXIS INC (NASDAQ:EXEL) meets key growth investing criteria with strong earnings, revenue growth, and profitability, making it a standout for investors following Louis Navellier's strategy.

ChartMill News Image19 days ago - ChartmillEXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Attractive Valuation

EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and reasonable valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.

Follow ChartMill for more